News Detail

Femasys swings to Q1 profit of 846,100; sales rise 24.5% to 424,889

PUBT · 05/08 20:07

Listen to the news

Femasys swings to Q1 profit of 846,100; sales rise 24.5% to 424,889

Femasys posted net income of USD 846,100 for quarter ended March 31, 2026, swinging from a net loss in the prior-year quarter.
Sales rose 24.5% to USD 424,889, driven primarily by FemBloc.
Operating loss narrowed to USD 4.22 million as research and development expense dropped 55.9% to USD 1.31 million.
Cash and cash equivalents totaled about USD 5.4 million at March 31, 2026; management expects cash resources to fund operations into third quarter of 2026.
Recent updates include initial commercial adoption and ACOG 2026 launch of FemaSeed Complete, initiation of patient enrollment in FemBloc FINALE pivotal trial, and a new Category III CPT code approval for FemaSeed intratubal insemination.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Femasys Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605081605PRIMZONEFULLFEED9716144) on May 08, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.

What's Trending

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.